Use

The present invention relates to the use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes. Specifically, the invention relates to a method for identifying an agent useful for the treatment or prophylaxis of a medical condition associated with elevated levels of blood glucose, the method comprising (i) contacting a candidate agent with a mammalian NAD(P)H oxidase or NAD(P)H oxidase complex; and (ii) determining whether said candidate agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.

Use

The present invention relates to the use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes. Specifically, the invention relates to a method for identifying an agent useful for the treatment or prophylaxis of a medical condition associated with elevated levels of blood glucose, the method comprising (i) contacting a candidate agent with a mammalian NAD(P)H oxidase or NAD(P)H oxidase complex; and (ii) determining whether said candidate agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.

Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase

A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Formulations Preserving Bioactivity and Methods of Their Preparation

A pharmaceutical composition comprising an alginate hydrogel core where a bioactive agent is entrapped. The water content of the hydrogel is at least 10% of equilibrium water content. The beads have an enteric coating and are intended for oral administration. The bioactive agent is bioactive proteins, antibodies or viable cells and it is intended to exert its activity in the duodenum and the upper intestines.

Compounds for use in the treatment of conditions associated with nadph oxidase

A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Compounds for use in the treatment of conditions associated with nadph oxidase

A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Thiophene-based compounds exhibiting nox4 inhibitory activity and use thereof in therapy

A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine

The compound N 2 -(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine- 2,4-diamineor a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidaseactivity.A pharmaceutical composition comprising the compound.

Process for isolating and purifying recombinant interleukin-7

COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND, METHOD FOR THE TREATMENT OF A DISORDER

composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio. um composto da fórmula (i) ou um sal farmaceuticamente aceitável do mesmo. o composto é usado em terapia, por exemplo, para o tratamento de uma condição ou distúrbio associado à atividade de nicotinamida adenina dinucleotídeo fosfato oxidase 4 ou 2 (nox4 ou nox2). é provida uma composição farmacêutica compreendendo o composto. compound, pharmaceutical composition, use of a compound, and method for treating a disorder. a compound of formula (i) or a pharmaceutically acceptable salt thereof. the compound is used in therapy, for example, to treat a condition or disorder associated with the activity of nicotinamide adenine dinucleotide phosphate oxidase 4 or 2 (nox4 or nox2). a pharmaceutical composition comprising the compound is provided.

Formulations preserving bioactivity and methods of their preparation

A pharmaceutical composition comprising an alginate hydrogel core where a bioactive agent is entrapped. The water content of the hydrogel is at least 10 % of equilibrium water content. The beads have an enteric coating and are intended for oral administration. The bioactive agent is bioactive proteins, antiboies or viable cells and it is intended to exert its activity in the duodenum and the upper intestines.

Speech immunity enhancement in linear prediction based dtmf detector

To determine whether a received signal represents a dual tone multi frequency (DTMF) code, a characteristic of the received signal is repeatedly measured over a period of time, thereby obtaining a plurality of parameter measurements. This may include separating the received signal into low band and high band signals and for each of the low band and high band signals, determining a plurality of squared magnitude measurements over the period of time. A deviation value is then determined for each of the plurality of parameter measurements, and an average deviation value is determined from the plurality of deviation values. The average deviation value is compared to a threshold value, thereby obtaining a comparison result. The received signal as alternatively designated as representing or not representing a DTMF code on the basis of the comparison result. The step of determining a deviation value for each of the plurality of parameter measurements may include, for each of the plurality of squared magnitude measurements, determining a deviation from a predefined (e.g., unit) circle only if the squared magnitude measurement is less than the radius of the predefined circle, and setting the deviation equal to zero for all other cases. The step of determining the average deviation value from the plurality of deviation values may include determining which of the plurality of deviation values is a maximum deviation value, and determining an average deviation value from the plurality of deviation values not including the maximum deviation value.

Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase

A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Compounds for use in the treatment of conditions associated with nadph oxidase

A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase.

Method for purification of a mixture of hydroxamate derivatized protein and native protein

Improvements in or relating to a chromatographic system

Method for purification of a mixture of hydroxamate derivatized protein and native protein

The invention relates to a method for purification of a mixture of hydroxamate derivatized protein/proteins and native protein which is characterized by treating the mixture with immobilized metal and thereby adsorbing the hydroxamate derivatized protein/proteins on the immobilized-metal and recovering the native protein. The protein could be IGF-L. It also relates to a process for the production of a native protein which is characterized by expression of the protein as a fusion protein, cleavage of the fusion protein by hydroxylanine, separation of native protein from hydroxamate derivatized protein by adsorbing the hydroxamate derivatized protein on immobilized metal and directly recovering the native protein. The use of immobilized metal affinity chromatography for separation of native protein from hydroxamate derivatized protein is also claimed.

Method for purification of a mixture of hydroxamate derivatized protein and native protein

The invention relates to a method for purification of a mixture of hydroxamate derivatized protein/proteins and native protein which is characterized by treating the mixture with immobilized metal and thereby adsorbing the hydroxamate derivatized protein/proteins on the immobilized-metal and recovering the native protein. The protein could be IGF-I. It also relates to a process for the production of a native protein which is characterized by expression of the protein as a fusion protein, cleavage of the fusion protein by hydroxylamine, separation of native protein from hydroxamate derivatized protein by adsorbing the hydroxamate derivatized protein on immobilized metal and directly recovering the native protein. The use of immobilized metal affinity chromatography for separation of native protein from hydroxamate derivatized protein is also claimed.

Method for purification of a mixture of hydroxamate derivatized protein and native protein

Derivados de sulfonamida novedosos que tienen actividad inhibidora selectiva de nox.

Se describe un compuesto de la fórmula (I) (ver Fórmula) o una sal farmacéuticamente aceptable del mismo. El compuesto es útil en la terapia, por ejemplo para el tratamiento de una afección o trastorno asociado con actividad de nicotinamida adenina dinucleótido fosfato oxidasa 4 o 2 (Nox4 o Nox2). Una composición farmacéutica que comprende el compuesto.

Novel sulfonamide derivatives having selective nox inhibiting activity

A compound of formula (I) or a pharmaceutically acceptable salt thereof.The compound is useful in therapy, e.g. for the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase4 or 2 (Nox4or Nox2) activity. A pharmaceutical composition comprising the compound.

Novel sulfonamide derivatives having selective nox inhibiting activity

A compound of formula (I) or a pharmaceutically acceptable salt thereof.The compound is useful in therapy, e.g. for the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase4 or 2 (Nox4or Nox2) activity. A pharmaceutical composition comprising the compound.

Novel sulfonamide derivatives having selective Nox inhibiting activity

A compound of formula (I) or a pharmaceutically acceptable salt thereof.The compound is useful in therapy, e.g. for the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase4 or 2 (Nox4or Nox2) activity. A pharmaceutical composition comprising the compound.

Novel sulfonamide derivatives having selective Nox inhibiting activity

A compound of formula (I) or a pharmaceutically acceptable salt thereof.The compound is useful in therapy, e.g. for the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase4 or 2 (Nox4or Nox2) activity. A pharmaceutical composition comprising the compound.

Process for isolating recombinant polypeptides